8th Jul 2005 14:00
8 July 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that it was notified on 7 July 2005 under Sections 198 to202 of the Companies Act that Aviva plc, through its subsidiary Morley FundManagement Limited sold 333,635 shares on 6 July 2005 and now holds inaggregate 14,666,124 ordinary shares of ‚£0.05p each in the capital of theCompany. These holdings represent 2.98 per cent of the issued ordinary sharecapital of the Company.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com.Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
AvivaShire